BioScience Health Innovations Inc

As of June 30, 2026, BioScience Health Innovations Inc carries a market capitalization of 46.46M, placing it among publicly traded companies globally. Its enterprise value stands at 46.01M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, BioScience Health Innovations Inc has 11.42M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 8.95, and the price-to-book ratio stands at 25.32.

These figures are as of June 30, 2026. The EV/Sales ratio of 8.99 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 46.01M versus a market cap of 46.46M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioScience Health Innovations Inc maintains a current ratio of 6.60, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, BioScience Health Innovations Inc posted a negative return on equity (ROE) of -12.37, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -10.85, reflecting losses generated across the asset base. Inventory turnover of 4.59 indicates how many times BioScience Health Innovations Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, BioScience Health Innovations Inc recorded an income tax benefit of -32,129.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -146,754.00 and -191,586.00 in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, BioScience Health Innovations Inc's stock has gained approximately 37.50% over the past 52 weeks.

Over the twelve months ended June 30, 2026, BioScience Health Innovations Inc generated 5.12M in revenue and converted that into -191,586.00 in net income, yielding earnings per share of -0.02. EBITDA reached -146,754.00, while operating income came in at -146,754.00.

As of June 30, 2026, BioScience Health Innovations Inc holds 712,378.00 in cash and equivalents against 260,402.00 in total debt, resulting in a net debt position of -451,976.00. Total book value stands at 1.83M, with working capital of 1.69M providing operational flexibility.

BioScience Health Innovations Inc produced -909,667.00 in operating cash flow over the twelve months ended June 30, 2026. After subtracting -53,808.00 in capital expenditures, free cash flow totaled -963,475.00 - equivalent to -0.09 per share.

Over the twelve months ended June 30, 2026, BioScience Health Innovations Inc posted a gross margin of 54.55, reflecting its pricing power and cost economics. The operating margin of -2.87 and net profit margin of -3.74 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.08: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.74, meaning BioScience Health Innovations Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

BioScience Health Innovations Inc's most recent stock split took place on September 26, 2025 with a 4:1 split ratio.

As of June 30, 2026, BioScience Health Innovations Inc has an Altman Z-Score of 95.76, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.